Displaying 1 - 15 of 390 results
Issue brief: Specific actions policymakers can take to end the nation’s drug overdose epidemic
This resources provides specific policy actions to increase access to treatment for substance use disorders, remove barriers to evidence-based pain care, and enhance state overdose prevention and treatment efforts.
Help save lives—prescribe and distribute naloxone
The AMA recommends for physicians to prescribe (and dispense if available) naloxone to anyone at risk of overdose; for public officials to make naloxone available in public places, such as schools and other educational settings, libraries and concert venues; for health insurance companies to ensure naloxone is not subject to co-pays or cost-sharing; and for pharmacies to make naloxone visible in front of the cash register and pharmacy counter.
Substance use in the United States: An update on data, policy and future directions
This AMA resource discusses trends relating to illicitly made fentanyl, methamphetamine, cocaine and other emerging toxic agents including xylazine, intoxicating hemp, kratom, tianeptine and medetomidine. Cannabis use also is a high concern with increasing data and research highlighting public health and patient harms.
Naloxone prescribing trends 2012-2024
View national and state-by-state data from leading health data clearinghouse IQVIA for naloxone dispensed from retail pharmacies.
Buprenorphine prescribing trends 2012-2024
View national and state-by-state data from leading health data clearinghouse IQVIA for buprenorphine prescribing trends.
State and National opioid Rx Trends 2012-2024
View national and state-by-state data from leading health data clearinghouse IQVIA for prescription opioids dispensed from retail pharmacies between 2012–2024.
ARC issue brief: Legislative examples to regulate kratom and tianeptine
The AMA considers unregulated kratom and tianeptine as dangerous substances and represent serious public health concerns. This issue brief provides examples of state legislative language for states to consider as part of their efforts to regulate kratom and tianeptine.
AMA Issue Brief: Kratom and tianeptine
A new issue brief from the AMA Advocacy Resource Center provides key information about kratom and tianeptine—two unregulated substances that have generated increasing reports of public health harms.
AMA Issue Brief: Substance use in the United States
A new issue brief from the American Medical Association providing updates on data, trends and policy directions.
AMA resource: Naloxone saves lives
AMA Issue Brief: Help save lives—prescribe and distribute naloxone.
AMA resource: mental health and substance use disorder parity
ARC Issue Brief: support medical criteria for medical necessity determinations for mental health and substance use disorders.
AMA Issue brief: Specific actions policymakers can take to end the nation’s drug overdose epidemic
AMA Issue brief: Federal parity report once again shows payers’ failures
The DOL/HHS/IRS 2024 Report to Congress showed that health plans and issuers continue to fail to comply with the Mental Health Parity and Addiction Equity Act of 2008 (MHPAEA) and subsequent Congressional enhancements to MHPAEA. Failures ranged from improper denial of care for mental health and substance use disorders (MH/SUD), inadequate MH/SUD networks, and failure to reimburse MH/SUD providers on par with medical/surgical providers. Read the AMA summary for more detail.
AMA summary of MHPAEA final rule
On September 9, 2024, the U.S. Departments of Labor, Health and Human Services, and Treasury released a final rule implementing the Mental Health Parity and Addiction Equity Act (MHPAEA). The 513-page rule includes numerous provisions strongly supported by the AMA and represents an opportunity for state legislatures and departments of insurance to strengthen their own parity laws.